• LAST PRICE
    0.6200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.6200
  • Day Range
    ---
  • 52 Week Range
    Low 0.1500
    High 0.9400
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.62
TimeVolumeIMUC
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMUC
Eom Pharmaceutical Holdings Inc
70.2M
-14.3x
---
United StatesTNXP
Tonix Pharmaceuticals Holding Corp
70.0M
-0.2x
---
United StatesLIFE
aTyr Pharma Inc
71.1M
-1.5x
---
United StatesMIRO
Miromatrix Medical Inc
68.4M
-2.4x
---
United StatesCADL
Candel Therapeutics Inc
72.2M
-6.0x
---
United StatesSPRB
Spruce Biosciences Inc
72.8M
-1.6x
---
As of 2023-01-27

Company Information

EOM Pharmaceutical Holdings, Inc., formerly ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company. The Company is focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. The Company’s portfolio consists of two product candidates: EOM613 and EOM147. EOM613 is an investigational, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and, based on past clinical data, have both an anti-inflammatory and pro-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect when needed. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM is designed to counteract with the severe inflammatory effects of viruses, such as a cytokine storm or hyperimmune response following infection with the novel coronavirus that cause COVID-19.

Contact Information

Headquarters
30721 Russell Ranch Road, Suite 140WESTLAKE VILLAGE, CA, United States 91362
Phone
818-264-2300
Fax
302-655-5049

Executives

Chairman of the Board, Chief Operating Officer
Eli Goldberger
President, Chief Executive Officer, Director
Irach Taraporewala
Chief Financial Officer, Treasurer
Wayne Danson
Chief Scientific Officer
Shalom Hirschman
Independent Director
Frank Douglas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$70.2M
Revenue (TTM)
$0.00
Shares Outstanding
113.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.07
EPS
$-0.04
Book Value
$-0.01
P/E Ratio
-14.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.